Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Han has participated in advisory boards for Boehringer Ingelheim GmbH, Pfizer Inc, GlaxoSmithKline plc, Genentech, Inc, Novartis AG, Forest Laboratories, Inc, and MedImmune, LLC. She has participated on speaker’s bureaus for Boehringer Ingelheim GmbH, Pfizer Inc, GlaxoSmithKline plc, the National Association for Continuing Education, Grifols and Forest Laboratories, Inc, and WebMD LLC. She has consulted for Novartis AG, Ikaria, Inc, United BioSource Corporation, and Nycomed International Management GmBH (now Takeda Pharmaceuticals International GmBH), and has received royalties from UpToDate Inc and Epocrates, Inc. Dr Flaherty has received research support from the National Institutes of Health, InterMune, and Centocore Biotech, Inc (now Janssen Biotech Inc). He has consulted for FibroGen Inc, Gilead Sciences, Inc, and Boehringer Ingelheim GmbH. He has participated on speaker’s bureaus for GlaxoSmithKline plc and Boehringer Ingelheim GmbH, and has received royalties from UpToDate, Inc. Dr Martinez has participated in advisory boards covering COPD or IPF topics for ABLE Associates, Actelion Pharmaceuticals, Ltd, Almirall, SA, Bayer AG, GlaxoSmithKline plc, Ikaria, Inc, Janssen Pharmaceuticals, Inc, MedImmune, LLC, Merck & Co, Inc, Pearl, Pfizer Inc, and Vertex Pharmaceuticals Incorporated. He has consulted on COPD or IPF topics for American Institutes for Research, AstraZeneca, Bayer AG, Carden Jennings Publishing Co., Ltd, CardioMEMS, Grey Healthcare Group, HealthCare Research and Consulting, Janssen, Merion, Nycomed (now Takeda Pharmaceuticals International GmbH), and Sudler and Hennessey. He has been a member of steering committees for studies sponsored by Actelion Pharmaceuticals, Ltd, Janssen Biotech, Inc., Forest Pharmaceuticals, Inc, GlaxoSmithKline plc, Gilead, Mpex, Nycomed (now Takeda Pharmaceuticals International GmbH). He has participated in Food and Drug Administration mock panels for Boehringer Ingelheim GmbH and Forest Pharmaceuticals, Inc. The University of Michigan received funds from the National Institutes of Health for COPD and IPF studies. He has served on speaker’s bureaus or in continuing medical education activities sponsored by American College of Chest Physicians; American Lung Association, AstraZeneca, Bayer AG, William Beaumont Hospital, Boehringer Ingelheim GmbH, Center for Health Care Education, CME Incite, Forest Pharmaceuticals, The France Foundation, GlaxoSmithKline plc, Lovelace Health System, MedEd, MedScape/WebMD LLC, National Association for Continuing Education Inc., CME Networks, LLC, Nycomed (now Takeda Pharmaceuticals International GmbH), Projects in Knowledge, Inc, St Luke’s Health System, the University of Illinois at Chicago College of Medicine, University of Texas Southwestern, University of Virginia, and UpToDate, Inc. He has served on DSMBs for Biogen and Novartis Corporation. He has received royalties from Castle Connolly Medical Ltd and Informa plc. All other authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.